New Publication: Clinical Trials in India
Posted by By nishithadmin at 13 August, at 12 : 15 PM Print
Warning: count(): Parameter must be an array or an object that implements Countable in /web/qlc/nishith.tv/htdocs/wp-content/themes/Video/single_blog.php on line 46
Warning: count(): Parameter must be an array or an object that implements Countable in /web/qlc/nishith.tv/htdocs/wp-content/themes/Video/single_blog.php on line 52
Clinical trials form an integral part of the drug discovery process worldwide. They aid pharmaceutical companies and medical practitioners to evaluate the efficacy of new treatments on humans. Clinical trials in India has been a buzzing topic in the pharmaceutical industry for decades. With a variety of factors in its favour, such as a diverse large population, availability of medical professionals and cost effectiveness India is a promising hub for clinical trials. With the passage of the New Drugs and Clinical Trial Rules in 2019, India is progressing towards a favourable regulatory ecosystem for clinical trials. In the backdrop of this new law, in this research paper we discuss the scope regulatory life cycle of clinical trials, modes of entry, emerging trends and challenges to clinical trials in India. We hope you find this paper useful. Please click here to access our paper. For any help or assistance, please email us on concierge@nishithdesai.com. Do visit us at www.nishithdesai.com.
|
Chambers and Partners Asia-Pacific: Band 1 for Employment, Lifesciences, Tax and TMT, 2022
AsiaLaw Asia-Pacific Guide 2022: Ranked ‘Outstanding’ for Media & Entertainment, Technology & Communications, Labor & Employment, Regulatory, Private Equity, Tax
Who’s Who Legal: Thought Leaders India 2022: Nishith M Desai (Corporate Tax – Advisory, Corporate Tax – Controversy and Private Funds – Formation), Vikram Shroff (Labour & Employment and Pensions & Benefits) and Vyapak Desai (Arbitration)
Benchmark Litigation Asia-Pacific: Tier 1 for Tax, Labour and Employment, International Arbitration, Government and Regulatory, 2021
Legal500 Asia-Pacific: Tier 1 for Tax, Data Protection, Labour and Employment, Private Equity and Investment Funds, 2021
IFLR1000: Tier 1 for Private Equity and Tier 2 for Project Development: Telecommunications Networks, 2021
FT Innovative Lawyers Asia Pacific 2019 Awards: NDA ranked 2nd in the Most Innovative Law Firm category (Asia-Pacific Headquartered)
RSG-Financial Times: India’s Most Innovative Law Firm 2019, 2017, 2016, 2015, 2014
DISCLAIMER
The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.